Low plasma adropin concentrations increase risks of weight gain and metabolic dysregulation in response to a high-sugar diet in male nonhuman primates. by Butler, Andrew A et al.
UC Davis
UC Davis Previously Published Works
Title
Low plasma adropin concentrations increase risks of weight gain and metabolic 
dysregulation in response to a high-sugar diet in male nonhuman primates.
Permalink
https://escholarship.org/uc/item/8qw6s614
Journal
The Journal of biological chemistry, 294(25)
ISSN
0021-9258
Authors
Butler, Andrew A
Zhang, Jinsong
Price, Candice A
et al.
Publication Date
2019-06-01
DOI
10.1074/jbc.ra119.007528
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Low plasma adropin concentrations increase risks of weight
gain andmetabolic dysregulation in response to a high-sugar
diet in male nonhuman primates
Received for publication, January 22, 2019, and in revised form, March 30, 2019 Published, Papers in Press, April 15, 2019, DOI 10.1074/jbc.RA119.007528
X Andrew A. Butler‡§1, Jinsong Zhang‡§, Candice A. Price¶2, Joseph R. Stevens‡, X James L. Graham¶,
X Kimber L. Stanhope¶2, Sarah King, Ronald M. Krauss, Andrew A. Bremer**, and Peter J. Havel¶3
From the ‡Department of Pharmacology and Physiology, Saint Louis University School of Medicine, St. Louis, Missouri 63104,
§The Henry and Amelia Nasrallah Center for Neuroscience, Saint Louis University, St. Louis, Missouri 63104, the ¶Department of
Molecular Biosciences, School of Veterinary Medicine and Department of Nutrition, University of California, Davis, Davis, California
95616, the Children’s Hospital Oakland Research Institute, Oakland, California 94609, and the **Department of Pediatrics,
Vanderbilt University, Nashville, Tennessee 37232
Edited by Jeffrey E. Pessin
Mouse studies linking adropin, a peptide hormone encoded
by the energy homeostasis–associated (ENHO) gene, to biolog-
ical clocks and to glucose and lipidmetabolism suggest a poten-
tial therapeutic target for managing diseases of metabolism.
However, adropin’s roles in human metabolism are unclear. In
silico expression profiling in a nonhuman primate diurnal tran-
scriptome atlas (GSE98965) revealed a dynamic anddiurnal pat-
tern of ENHO expression. ENHO expression is abundant in
brain, including ventromedial and lateral hypothalamic nuclei
regulating appetite and autonomic function. Lower ENHO
expression is present in liver, lung, kidney, ileum, and some
endocrine glands. Hepatic ENHO expression associates with
genes involved in glucose and lipid metabolism. Unsupervised
hierarchical clustering identified 426 genes co-regulated with
ENHO in liver, ileum, kidneymedulla, and lung. GeneOntology
analysis of this cluster revealed enrichment for epigenetic
silencing by histone H3K27 trimethylation and biological pro-
cesses related to neural function. Dietary intervention experi-
mentswith 59 adultmale rhesusmacaques indicated lowplasma
adropin concentrations were positively correlated with fasting
glucose, plasma leptin, andapolipoproteinC3 (APOC3) concen-
trations. During consumption of a high-sugar (fructose) diet,
which induced 10% weight gain, animals with low adropin had
larger increases of plasma leptin and more severe hyperglycemia.
Declining adropin concentrations were correlated with increases
ofplasmaAPOC3andtriglycerides. Insummary,peripheralENHO
expression associateswith pathways related to epigenetic andneu-
ral functions, and carbohydrate and lipid metabolism, suggesting
co-regulation innonhumanprimates.Lowcirculatingadropinpre-
dicts increased weight gain and metabolic dysregulation during
consumption of a high-sugar diet.
The energy homeostasis–associated (ENHO) gene contains a
single highly-conserved ORF (adropin1–76). In silico analysis indi-
cates a secreted domain (adropin34–76) released from a secretory
signal (adropin1–33) by proteolysis (1, 2). Adropin34–76 has bioac-
tivity that influences carbohydrate and lipid metabolism when
administered to rodents and cultured cells (1, 3–12). Adropin
immunoreactivity has been measured in the circulation of
humans, nonhuman primates, and mice (1, 8, 11, 13). However,
retention of adropin1–76 in plasma membrane fractions has been
observed (14). The secretory processes and protein structure of
adropin thus remain under investigation.
Experiments performed in male C57BL/6J (B6) mice impli-
cate a role for adropin in metabolic homeostasis. Treating diet-
induced obese (DIO)4 B6 mice with exogenous adropin34–76
reduce adiposity (1). Conversely, adropin deficiency increases
adiposity without altering food intake (11). In mice and cul-
tured cells, adropin34–76 increases activity of the pyruvate de-
hydrogenase complex, enhancing the coupling of glycolysis
with the tricarboxylic acid cycle and oxidative glucose metabo-
lism (1, 3, 9, 10, 12). Treatmentwith adropin34–76 also enhances
insulin signaling, glucose tolerance, and whole-body oxidative
glucose disposal in DIO B6 mice independently of weight loss
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(1, 9).Male B6mice lacking either one or both functional copies
of the Enho gene exhibit insulin resistance and impaired glu-
cose tolerance (11, 15). Partial loss of adropin signaling is thus
sufficient to result in impaired glucose homeostasis.
The initial studies examining regulation of hepatic adropin
expression in mice indicated rapid effects of fasting and intake of
dietary macronutrients (1, 16–19). More recent studies indicate
rhythmicity of hepatic adropin expression under the control of
core elements of the biological clock (8). Diurnal cycles of tran-
scriptional activation or repression by retinoic acid–related
orphan receptors (ROR) or REV-ERB contribute to the rhythmic-
ity of the biological clock (20–22) and to hepatic Enho expression
(8). Members of the ROR (, , and ) and REV-ERB ( and )
families bind competitively to common genomic elements, regu-
lating transcription of genes involved in carbohydrate and lipid
metabolism; these nuclear receptors also possess ligand-binding
domains responsive to cellular lipid and redox conditions (20).
InvolvementofRORandREV-ERB in regulatingENHO transcrip-
tionprovides aplausiblemechanism linking adropin expression to
biological clocks.Asadropinregulatesglucoseand fatoxidation (3,
9, 10, 12), it may have a role in translating cues from biological
clock genes into rhythms in carbohydrate and lipid metabolism.
The relationships between adropin andmetabolism in humans
are less clear and remain under investigation. Several studies have
reported that fasting plasma adropin concentrations are lower in
humans with insulin resistance (23–26). Relationships have been
observed between circulating adropin concentrations and fasting
glucose levels in children with Prader-Willi syndrome, as well as
circulating levels of the gut peptide obestatin in children (27). A
more recent study using diverse age groups observed an inverse
associationbetweenplasmaadropin concentrations and indicesof
atherogenic hypercholesterolemia (total cholesterol, LDL-C, and
nonHDL-C) in males possibly mediated by suppression of ENHO
expressionbycholesterol (8). Inadults, plasmaadropinconcentra-
tions are positively correlated with dietary fat intake and inversely
with carbohydrate intake (26, 28) and increase during fructose
consumption (29). Differences in dietary preferences (fat versus
carbohydrates) could be a confounding variable in cross-sectional
human studies examining the relationship between circulating
adropin levels and indices of cardio-metabolic risk.
Here, we report the results from two studies investigating adro-
pin physiology in nonhuman primates. Nonhuman primates are
useful models for translating preclinical data obtained using
rodents toclinical studies inhumans (30–32).Otheradvantages to
using nonhuman primate models include minimizing variability
from diet and personal history and access to a number of tissues
that cannot normally be obtained in humans. Baboons (Papio
anubis) and rhesus macaques (Macaca mulatta) belong to a
closely related tribe (Papionini) that diverged from lineages
leading to the evolution of humans and great apes 25–28
million years ago (33). We used the transcriptome atlas of a
nonhuman primate (baboon) (34) to profile diurnal ENHO
expression. We then investigated the relationships between
plasma adropin concentrations and indices and risk factors
for metabolic dysregulation in a well-characterized rhesus
macaque model of a high-sugar (fructose) diet–induced obe-
sity, insulin resistance, and dyslipidemia (13, 31, 35).
Results
ENHO expression profile in baboon tissues
Comparisons of FPKM data averaged over 24 h between
baboon tissues indicate abundant ENHO expression in the cen-
tral nervous system, particularly in the amygdala and lateral and
ventromedial areas of the hypothalamus (VMH) (Fig. 1A).
Lower expression levels are observed in liver, kidney (medulla
and cortex), ileum, lung, and testes and the pituitary, pineal, and
adrenal glands (Fig. 1A). ENHO expression exhibits a predomi-
nantly diurnal pattern in most neural and peripheral tissues (Fig.
1B). However, in two areas of the brain exhibiting high expression
(amygdala and VMH), expression was observed during both the
light and dark periods.
Studies inmice indicate liver adropin expression is nutritionally
regulated (1, 8). In baboon liver, ENHO expression is limited to
zeitgeber time 0 (ZT0, transition between dark and light phases;
the firstmealwasprovidedatZT3) andZT6 (3hbefore the second
meal at ZT9) (Fig. 2A). Amatrix of genes ranked by their Pearson
coefficient comparedwith ENHO indicates over 1200 genes share
this profile, using a correlation coefficient (r) of0.7 as selection
criteria (Fig. 2B). Hepatic ENHO expression also appears to be
mutually exclusive (r0.7) for a similar number of genes (Fig.
2B). Global analysis identified “MIKKELSEN_MCV6_HCP_
WITH_H3K27ME3” and “MIKKELSEN_MEF_HCP_WITH_
H3K27ME3”as the top twogene sets enriched in thepopulationof
ENHO co-regulated genes in liver (Table S1). The promoter
regions of these genes contain markers of high CpG density and
epigenetically silent histone H3K27 trimethylation (H3K27me3).
Thesegenesmay thus shareacommonregulatorypathway involv-
ingCpG-coupledepigeneticmechanisms,possibly acting inacon-
certed fashion.AbroadCpG island domain found 5 of theENHO
gene spans the entire promoter and exon 1 regions. This CpG
island sequence is highly conserved across 46 different species,
indicated by high phastCon and SiPhy scores (data not shown).
DNA methylation and ChIP-Seq results from HepG2 cells pub-
lished by the ENCODE Consortium (36) indicated heavy methyl-
ation of the ENHO gene promoter at the CpG island region. His-
tone H3 was also strongly methylated at H3K27, generating
extensive H3K27me3 repressive markers surrounding the entire
ENHO promoter region. The active histone marker (acetyl-
H3K27 (H3K27ac)) is absent at the ENHO promoter (data not
shown).
Studies in rodents have linked adropin to glucose and lipid
metabolism (1, 3, 9, 10, 12). In the baboon liver, genes involved in
glucosemetabolism (for example hexokinase-1, phosphofructoki-
nase, and GLUT1), and in G-protein–coupled receptor and
receptor tyrosine kinase signaling exhibit expression profiles
similar toENHO (Fig. S1). Lipid and lipoprotein gene sets/path-
ways are also enriched in genes that are negatively correlated
with ENHO expression (e.g. “REACTOME_LIPOPROTEIN_
METABOLISM”). To confirm this, we extracted the list of
genes contributing to the negative association (NES  2.16,
padj 6.1e-03) reported by GSEA. All of these genes exhibit an
expression profile that is negatively correlated with ENHO
(Table S2).
Other nonneural tissues with relatively robust levels of diur-
nal expression (Fig. 1A) also exhibit dynamic profiles of expres-
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sion with discrete peaks (Fig. S2A). An unbiased analysis exam-
ining gene clusters correlating with ENHO expression in all
tissues indicates strong relationships between liver, kidney
medulla, lung, and ileum (Fig. S3A). Using r 0.9 as selection
criteria in the correlation matrix, 426 genes exhibit an expres-
sion profile common in these tissues (Fig. S3B andTable S3). As
observed in liver, this cluster is enriched for epigenetic silencing
by histone H3K27me3 (p 4.9 1046). However, this cluster
is also enriched for genes linked to neural function and neuro-
degenerative diseases (supporting Results, GO_426_geneset).
Of note, this cluster includes genes encoding secreted peptides’
cholecystokinin (CCK) involved in appetite control (37) and
growth differentiation factor 11 (GDF11) implicated in devel-
opment and aging (38). Diurnal ENHO expression in the ileum
also correlates strongly with expression of CCK and apolipo-
proteins (ApoA4 and ApoE) (Fig. S2B).
Low plasma adropin concentrations signal metabolic
dysregulation in rhesusmacaques
We next tested the hypothesis that low plasma adropin con-
centrations signal increased risk for metabolic dysregulation.
Fasting plasma adropin concentrations were measured in rhe-
sus macaques at baseline and when challenged with a high-
sugar (fructose) beverage diet for 3months. Biometric andmet-
abolic parameters from the animals used for this study have
been published (39). In brief, dietary fructose supplementation
rapidly induces weight gain, increases of fasting plasma insulin,
leptin, triglycerides (TG), ApoC3, and ApoE, and decreases
plasma adiponectin concentrations (39).
At baseline, simplemodeling identified correlations between
fasting plasma concentrations of adropin and leptin ( 
0.476, p 0.001, Fig. 3A), glucose (0.523, p 0.001, Fig.
3B), and ApoA1 (  0.352, p  0.01). Fasting glucose con-
centrations100 mg/dl are used as diagnostic criteria for type
2 diabetes in rhesus macaques (40–43). In this study, animals
with type 2 diabetes all have lowplasma adropin concentrations
(Fig. 3B). There is, however, no consistent correlation between
fasting plasma concentrations of adropin and insulin at baseline
(Fig. 3C). Elevated circulating leptin concentrations in animals
with low plasma adropin concentrations suggest greater body
adiposity. However, body weight does not correlate with plasma
adropin concentrations (Fig. S4,A and B).
This observation could indicate a correlation between
plasma adropin concentration and partitioning of nutrients
between fat and lean tissues. A nutrient partitioning phenotype
is observed in male B6 adropin transgenic mice. Adropin
knockout B6 mice exhibit increased fat mass while having nor-
mal body weight (11). Comparison of body composition in
adropin transgenic (AdrTG) B6mice and wildtype (WT) litter-
mate controls (mean age, 16.6 weeks; S.D., 3.4 weeks; range
11.4–20.4 weeks) further supports this finding. Body weight is
not significantly different (age-adjusted weight for AdrTG,
31.2 0.7 g; WT, 30.8 0.7 g) (Fig. S4C). However, relative to
controlsAdrTGexhibit reduced fatmass (3.9 0.4 versus 5.6
0.4 g, age- andweight-adjusted, p 0.01) and increased fat-free
mass (19.1 0.2 versus 17.9 0.2 g, age- and weight-adjusted,
p 0.005) (Fig. S4, C–E).
During fructose consumption, animals with low adropin con-
centrations exhibitedmorepronounced increases of plasma leptin
(Fig. 3A). Fasting hyperglycemia appears more severe in animals
with type2diabetes, andagain isonlyobserved inanimalswith low
plasma adropin concentration (Fig. 3B).
Figure 1. Relative ENHO expression in baboon tissues (A) and diurnal
expression profile within tissues (B). The heat map in A is a single column
that shows relative expression between tissues and is read from top to bot-
tom. Thesedata arederived fromFPKMaveragedover 24hwithin each tissue.
The heat maps in B show relative expression as a deviation from the 24-h
mean (z-score) during a24-hperiodwithin each tissue and shouldbe read left
(ZT0) to right (ZT24). The heat maps illustrate the diurnal profile of ENHO
expression. Peak ENHO expression (red) is observed in the daytime in most
tissues. Lights-on (day time) and lights-off (night time) are indicated by the
yellow and black bars, respectively.
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We employed multiple linear regression to determine corre-
lates of plasma adropin concentrations based on age, body
weight, and indices of glucose homeostasis and lipid metabo-
lism at each time point. In general terms, indices of adiposity
and lipoprotein metabolism are strong predictors of plasma
adropin concentration (R2 0.74, 0.71, and 0.74 at baseline and
after 1 or 3 months of fructose, all p 0.001) (Table 1). Leptin,
HDL-C, ApoA1 and ApoC3 are highly significant predictors of
plasma adropin concentrations, irrespective of diet (Table 1).
After 3 months of fructose consumption and dyslipidemia, TG
andApoB are also significant predictors of plasma adropin con-
centrations. Plasma adropin andApoC3 concentrations exhibit
an inverse correlation that is enhanced during fructose con-
sumption (Fig. 3D). However, relationships between plasma
concentrations of adropin, HDL-C, and ApoA1 appear less
robust when assessed individually (Fig. S5).
Relationships between baseline plasma adropin concentra-
tion and fructose-induced weight gain, insulin resistance, and
dyslipidemia were explored by separating the animals into
three groups (tertiles) (low adropin, n  20; medium adropin,
n  19; and high adropin, n  20) (Table 2, 3). Animals in the
low-adropin group had significantly higher fasting glucose con-
centrations compared with the high-adropin group, irrespec-
tive of diet (Table 2). Differences in fasting insulin between
adropin groups was significant (p  0.05) when two outliers
from the low-adropin group with insulin values 600 milli-
units/ml were excluded (1.5 times the interquartile range).
However, it is notable that these extreme insulin values after 3
months on the fructose beverage diet were limited to animals in
the low-adropin group (Fig. 3C). Fructose-induced increases of
plasma leptin concentrations (	leptin) adjusted for age and
baseline values are also significantly higher in animals in the
low-adropin group (Table 2). Plasma ApoC3 concentrations
exhibit marked (50%) and significant differences between adro-
pin groups (Table 3), consistent with an inverse association
(Fig. 3D). ApoC3 regulates lipoprotein metabolism to increase
TG (44, 45). Animals with low baseline plasma adropin levels
appear to have a greater propensity for developing hypertrig-
lyceridemia after 3 months of fructose consumption (Fig. S6).
However, there are no significant correlations between adropin
and plasma concentrations of IDL or VLDL particles (Fig. S6).
Animals in the high-adropin group appear to have consis-
tently higher LDL-C levels during the study, although the dif-
ference is significant only at the 3-month time point (Table 3).
Fasting plasma adropin concentrations also exhibit significant
positive relationships with LDL particles at baseline (LDL-4C,
  0.386; LDL-4B,   0.485; LDL-4A,   0.377; p  0.005;
LDL3B,  0.308, p 0.05; see Table S4 for plasma lipoprotein
particle concentrations at baseline) but not during fructose
consumption (data not shown).
Figure 2. Hepatic ENHO expression shares a dynamic expression profile
with>1200genes.A,diurnalprofileofhepaticENHOexpressionshownasa line
graph.Meal timesare indicatedbygreenarrows.B,heatmapcomparingprofileof
ENHO expression (top) with genes ranked by their correlation coefficient (r, high
to lowwhen read from the top down) with ENHO. The coefficient of determina-
tion (R2) is shown to the right. Lights-on (day time) and lights-off (night time) are
indicated by the yellow and black bar at the top of the figure. There are 1276
genes showing amarked positive association andwhose expression ismutually
inclusive (r0.7) with ENHO. For a similar number of genes, ENHO expression
appears be mutually exclusive (ENHO is highly expressed as indicated by red
coloring and their expression is repressed as indicated by blue coloring).
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Correlations between fructose-induced changes of plasma
adropin and ApoA1 concentrations
Overall, a small but highly significant increase of plasma
adropin concentrations is observed after 1 month of fructose
supplementation (diet effect, p 0.001 by Friedman’sANOVA;
mean  S.D. for plasma adropin concentration in nano-
grams/ml at baseline, 1.69 0.92; 1 month of fructose, 1.91
0.99; 3 months of fructose, 1.68  0.90; 1 month versus pre-
and 3 months of fructose, p  0.001, n  59). In humans, a
“responder/nonresponder” situation is observed with the effect
Figure 3. Relationships between plasma adropin concentrations and fasting plasma concentrations of leptin (A), glucose (B), insulin (C), and ApoC3
(D) in male rhesus macaques (n  59). Scatterplots present the relationships at baseline (chow-fed) and after 1 and 3 months of consuming fructose-
sweetenedbeverages (300 kcal/day). Fasting plasmaglucose concentrations exceeding 100mg/dl (indicatedwith red symbols, orange shading in B) have been
used as a diagnostic criteria for type 2 diabetes in rhesusmacaques (38–41). Of the seven animals with fasting glucose100mg/dl after 3months of fructose,
four had glucose levels100 mg/dl at baseline (50%). The fasting glucose levels of the other three animal at baseline were higher (85, 83, and 92 mg/dl)
relative to the group average (mean 80 mg/dl, S.D. 15 mg/dl).
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of consuming fructose beverages as 25%of daily energy require-
ments on plasma adropin concentrations (29). The impact of
fructose consumption on plasma adropin concentrations also
varies markedly between animals (Fig. S7, A and B; 	adropin
range from 0.7 to 
1.3 ng/ml). Multiple linear regression
identified 	ApoA1 as the strongest predictor of 	adropin (t
2.846, p  0.005). Comparing 	ApoA1 and 	adropin con-
firmed a modest association (Fig. 4, A and B). Although highly
significant (p  0.001), the model explains only 31% of the
variation in 	adropin (R2  0.306). Independent variables
included in the model were 	body weight, age, and 	 pooled
from the 1-month- and 3-month–sampling for fasting glucose,
plasma concentrations of hormones involved in glucose and
lipid homeostasis, apolipoproteins, total lipids, and lipoprotein–
cholesterol levels.
Declining adropin signals increase risk for fructose-induced
atherogenic dyslipidemia
Of note, animals exhibiting decreases of plasma adropin con-
centration have larger increases of plasma concentrations of
TG (Fig. 4,C andD) andApoC3 concentrations (Fig. 4,E and F).
The physiological significance of fructose-induced changes of
plasma adropin in individual animals was further investigated
by ranking animals by 	adropin after 1 month of fructose con-
sumption. The animals were separated into three groups that
exhibit a robust but transient increase of plasma adropin
(“high-responders,” n  20), an intermediate but persistent
increase (“mid-responders,” n  19), or decreases of adropin
(“low-responders,” n 20) (Fig. 5, A and B).
Fructose-induced changes of adropin, ApoA1, and HDL-C
(Apoa1 is a major apoliprotein in HDL) were similar between
groups (Fig. 5, C–F). However, the differences for ApoA1 and
HDL-Cwere not statistically significant. For plasma concentra-
tions of ApoC3 and TG, a different pattern was evident. Ani-
mals exhibiting the largest increases of plasma adropin concen-
trations at 1 month have lower ApoC3 (estimated marginal
means of fasting ApoC3 for low-responders, 6.3  0.4 mg/dl;
mid-responders, 6.0  0.4; high-responders, 4.7  0.4 mg/dl;
low versus high, p  0.01). They also exhibit less-pronounced
Table 1
Calculation of plasma adropin concentration using multiple linear regression in male rhesus macaques on chow, and after 1 or 3 months of
consuming a fructose beverage (300 kcal/d) (n 59)
Log-transformed data were used for the analysis. The 1st column presents the independent variables, and the next 3 columns present results from the analysis of data from
animals collected at specific time points in the study: baseline (chow) and after 1 or 3months of fructose consumption. R2 and p values are shown for each calculation in the
1st row. At each time point in the study, modeling was successful in calculating plasma adropin concentration using the variables described in the 1st column, explaining
70–74% of the variation in plasma adropin concentration between individual animals. B is the coefficient, representing the independent contributions of the independent
variables (age, body weight, glucose, insulin, etc.) to the prediction of the dependent variable (adropin). The t statistic is the coefficient divided by its standard error.
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increases of ApoC3 during fructose consumption (Fig. 5,G and
H). A similar pattern was evident for TG (estimated marginal
means of fasting TG for responders, 205  25 mg/dl; mid-re-
sponders, 126 25; high-responders, 113 25 mg/dl; low ver-
susmedium and high, p 0.05). Low-adropin responders have
larger increases of plasmaTG in response to fructose consump-
tion (Fig. 5, I and J). For both ApoC3 and TG, repeated mea-
sures ANOVA indicated a significant impact of time on the
fructose diet (p 0.001) and a significant interaction between
diet and 	adropin-group (low-, medium-, or high-responder;
p 0.05). Analysis of lipoprotein particles fractionated by size
also indicated correlations with risk for atherogenic dyslipi-
demia during fructose consumption with low-responders
exhibiting more pronounced increases of small, dense LDL
(LDL4) (Fig. S8).
Discussion
There are two major findings from these studies. First, data
from the baboon study are indicative of a diurnal pattern of
ENHO expression inmost tissues examined. These studies sug-
gest co-regulation of ENHO expression and genes involved in
Table 2
Indices of glucose control in rhesus macaques grouped by low, medium, or high baseline plasma adropin concentration
Age is reported as mean S.D.Measurements at baseline, 1, and 3months are shown as estimatedmarginal means S.E.; covariates are indicated in the table subheading.
Changes relative to baseline (	) after 3 months on fructose are estimated marginal means  S.E. adjusted for age and baseline values. The increase in plasma leptin
concentrations indicated in the final row (	) is after 3 months of fructose consumption. * indicates significantly different from medium (p  0.05) and high (p  0.01)
adropin groups. ** indicates significantly different frommedium and high adropin groups (p 0.005). #, ## indicates significantly different from low adropin group (#, p
0.05; ##, p 0.01).
aDifferences between all groups are highly significant, p 0.001.
EDITORS’ PICK: Adropin signals risk for metabolic dysregulation in primates
9712 J. Biol. Chem. (2019) 294(25) 9706–9719
 at U
niversity of California, D
avis on June 21, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
hepatic carbohydrate and lipoprotein metabolism. Second,
data from the rhesus macaque study indicate low plasma adro-
pin concentrations are associated with indices of lipoprotein
metabolism and features of the metabolic syndrome (fasting
hyperglycemia, dyslipidemia, and hyperleptinemia). The rela-
tionship between plasma concentrations of adropin and leptin
are independent of body weight. This observation could indi-
cate a correlation between circulating adropin and nutrient
partitioning between fat and lean tissues, with lowplasma adro-
pin concentrations related to increases of body adiposity.
Overall, the expression profiling results in a nonhuman pri-
mate are consistent with previous data from mice indicating
regulation by the biological clock (8). In male B6 mice, liver
ENHO expression peaks late in the dark cycle when nocturnal
mice are most active. In diurnal baboons, ENHO expression
peaks during the daytime in the liver, and in most other tissues
examined with significant levels of ENHO expression. The
expression profiling data are also consistent with elevated
plasma adropin concentrations around meal times during the
daytime, and a steady decline at night-time, in rhesusmacaques
(8). The finding that liver ENHO expression peaks 3 h prior to
both meals may be coincidental. Another caveat is the small
sample size. It is nevertheless consistent with a gene linking
metabolismwith nutrient intake. Further studies examining the
link between meal timing and hepatic adropin expression are
clearly needed.
Table 3
Indices of lipid metabolism
Data shown are estimate marginal means S.E. adjusted for age and body weight. Data are significantly different from low- and medium-adropin groups, *, p 0.05; data
are significantly different from medium- and high-adropin groups, **, p  0.05 versus medium  0.001 versus low; and data are significantly different from low-adropin
group, #, p 0.005.
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The finding that ENHO expression shares a dynamic expres-
sion profile with a cluster of genes regulated by histone H3K27
trimethylation is novel. H3K27me3 is an evolutionarily con-
served pathway for repressing gene expression (46, 47). Regu-
lation of gene expression by H3K27me3 has classically been
linked to control of gene expression during development and in
tumorigenesis. Interesting hypotheses raised by this observa-
tion include links between epigenetic silencing of transcription
and variation in ENHO expression between tissues, and with
plasma adropin concentrations that vary markedly in humans
(8, 48).
ENHO expression in the periphery also clusters with genes
linked to neural functions. The significance of this finding is
unclear. One possible interpretation is evidence of interactions
between adropin signaling and the activity of the somatic and
autonomic nervous systems in peripheral tissues.
Carbohydrate and lipid metabolism in the liver are con-
trolled by elements of the biological clock (49, 50). In this study,
peak hepatic ENHO expression during the daytime appeared to
coincide with phases of increased receptivity to endocrine and
autonomic inputs. Expression of enzymes involved in signal
transduction pathways emanating from G-protein–coupled
receptors and receptor tyrosine kinases peaks exhibits similarly
dynamic profiles with peaks in expression coinciding with
those for ENHO. Expression profiling data also indicate the
potential for co-regulation of the expression of adropin and
genes involved in carbohydrate and lipid metabolism. This
observation may also explain the associations between plasma
adropin concentrations and apolipoproteins observed in rhesus
macaques.
Another interesting observation is the tight correlation
between ENHO expression and gut-secreted peptides linked to
the regulation of satiety and intestinal motility (CCK and
ApoA4) and lipid absorption (ApoA4 and ApoE) in the ileum
(37, 51). A caveat to interpreting these data are that we do not
knowwhether differences inENHO expression translates to the
level of protein. However, diurnal rhythms in ApoA4 andApoE
mRNA and protein have been reported in rat tissues (52–54).
The second study presented here examined the relationships
between plasma adropin concentrations and circulating
parameters of carbohydrate and lipid metabolism. We investi-
gated whether plasma adropin concentrations are predictive of
metabolic dysregulation and sensitivity in response to a high-
sugar diet. Experiments using B6 mice indicate that even mod-
est suppression of adropin is related to insulin resistance and
more pronounced glucose intolerance with diet-induced obe-
sity (11, 15).
Rhesus macaques weigh less and have fasting glucose levels
that are typically 20–30 mg/dl lower than humans (40–43).
Type 2 diabetes occurs spontaneously, particularly in animals
with elevated body fat mass (43). There is an inverse relation-
ship between plasma adropin concentrations and risk of dys-
regulation of glucose metabolism (i.e. fasting hyperglycemia/
type 2 diabetes) in rhesus macaques. Animals with low adropin
exhibit increased incidence of overt type 2 diabetes and ele-
vated plasma leptin, indicative of increased body adiposity. In
these animals, fructose consumptionmay be considered a “risk-
amplifier.” Fructose consumption induces further weight gain,
increases adiposity, and accelerates metabolic dysregulation.
Animals with low plasma adropin concentrations may thus
exhibit amore rapid progression of pre-existingmetabolic con-
ditions toward a more overt disease state (type 2 diabetes and
adverse changes of apolipoprotein profiles associated with ath-
erosclerosis in humans). Although the relationship with insulin
is less clear, the development of more severe hyperinsulinemia
with fructose consumption is limited to animals with low
plasma adropin concentrations. Low plasma adropin is also
closely related to elevations of plasma ApoC3, indicating
increased risk for hypertriglyceridemia resulting from the
effects of ApoC3 to augment hepatic lipogenesis and impair TG
clearance (45, 55–57).
High circulating leptin/adiponectin levels in animals with
low adropin despite normal body weight suggest an increased
adipose–to–lean mass ratio. A “TOFI” (thin-outside–fat-in-
side) phenotype would also be consistent with insulin resis-
tance (58). High plasma adropin concentrations are associated
with a leaner phenotype in young men; however, this associa-
tion is not observed later in life (8, 59). Whether low plasma
adropin levels signal increased visceral fat accumulation in rhe-
sus macaques, or in young adult humans, will require further
study.
Plasma adropin concentrations at baseline are positively cor-
related with age (  0.373, p  0.005). Animals in the low
plasma adropin tertile were actually significantly younger (2
Figure 4. Relationships between fructose-induced changes in ApoA1 (A
and B), TG (C andD), andApoC3 (E and F). The data shown are for fructose-
induced changes (	) after 1month (A, C, and E) and3months (B, D, and F). The
proportion of variance dependent on the variable (coefficient of determina-
tion, R2 with p value) is shown in each graph.
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years) compared with the mid- and upper tertiles. Indeed, ani-
mals in the low-adropin group had yet to enter middle age
(mean age, 10.4 years, range 7.8–14.8 years; rhesusmacaque life
expectancy is30 years). Aging per se is therefore not a factor
in the relationships between low circulating adropin levels and
increased risk for metabolic dysregulation. However, this study
suggests increases of obesity-related co-morbidities that could
reduce life expectancy in animals with low circulating adropin.
The positive correlation between plasma adropin concentra-
tion and age in this study differs from previous results from
humans and rodents showing a decline with aging (8, 48, 60,
61). There are two potential explanations for the discrepancy
that also serve as a precautionwhen comparing results between
studies. First, type 2 diabetes is often used as an exclusion cri-
terion in studies involving human subjects, introducing poten-
tial bias. Plasma adropin concentrations have been reported to
be lower in people with type 2 diabetes (15, 23–25). Aging and
metabolic dysregulation associatedwith type 2 diabetesmay act
through independent and common mechanisms to suppress
adropin expression. The relative mixture of young or aged and
healthy or diabetic subjects could thus influence the observed
associations. Second, another bias is introduced because the
animals used in rodent studies are almost always highly inbred
(e.g. B6mice) and aremaintained in amore controlled environ-
ment. This would reduce the contribution of genetic and envi-
ronmental variability to the effects of aging on adropin expres-
sion and circulating adropin levels.
Studies using mice and cultured rat atrial cells indicate adro-
pin rapidly improves insulin action and enhances glycolysis (3,
9, 10). Enhanced oxidation of glucose in skeletal muscle pro-
vides a plausible mechanism underlying the lean phenotype
suggested by the leptin/adiponectin data and observed in this
study using adropin transgenic mice. Enhanced oxidative glu-
cose disposal in muscle could also improve lipid metabolism
through shuttling carbohydrates away from lipogenesis. Fur-
ther studies exploring the relationship between plasma adropin
concentrations and glucose metabolism are clearly needed. In
addition, further experiments examining the acute response of
nonhuman primates with low adropin to the administration of
exogenous adropin34–76 are warranted based on these results.
It is also important to consider the potential impact of a com-
bination of risk factors, including elevated leptin and ApoC3
levels, when interpreting the phenotype of animals with low
plasma adropin concentrations. Relationships between low cir-
culating adropin concentrations and the heightened risk for
metabolic dysfunction cannot be interpreted as a “direct” con-
sequence of altered adropin action. For example, ApoC3 is pos-
itively associated with atherogenic dyslipidemia and the risk of
cardiovascular disease (62–64). Accordingly, low adropin levels
Figure5. Lipidparameters in subpopulationsof rhesusmacaques exhib-
iting low, medium, or high responses of plasma adropin concentrations
after 1 month of fructose consumption. Animals were ranked by changes
of plasma adropin concentrations after 1 month of fructose consumption.
Theywere then subdivided into three groups: high-responders, n 20, green
lines/symbols; mid-responders, n 19, blue lines/symbols; and low-respond-
ers, n  20, red lines/symbols. Shown are the averages for each time point
basedon the rankingat the1-month timepoint. Plasmaconcentrationsof the
variable defined in the y axis label are shown in A, C, E, G, and H. Fructose-
induced	s of plasma concentrations of the variable defined in the y axis label
(1- and 3-month values subtracted from baseline) are shown in B, D, F, H, and
J. “High-responders” exhibit a marked increase in plasma adropin concentra-
tion at the 1-month time point (B). ***, p 0.001 between all groups; #, p
0.05 versus mid- and high-responders; *, p  0.05; **, p  0.01 versus low-
responders (within time points). #, low- versus medium-responder, p 0.05,
versus high-responder, p 0.01 (ANOVA with repeated measures).
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may be secondary to metabolic dysregulation driven by
independent stochastic variables. Indeed, a modest decline of
plasma adropin concentrations associated with more severe
dyslipidemia. However, adropin-deficient mice exhibit insulin
resistance and exaggerated impaired glucose tolerance with
diet-induced obesity (11), indicating low adropin increases risk
factors for metabolic disease. Clearly, further studies using a
primatemodel are needed to ascertain causality between differ-
ences in plasma adropin concentrations and risk of metabolic
dysregulation. These would include interventions to determine
the physiological impact of increasing plasma adropin concen-
tration in animals with low plasma adropin concentrations.
Plasma adropin concentrations are correlated with self-re-
ported and observed macronutrient selection in humans (26,
28). These studies suggest a relationship between plasma adro-
pin concentrations and the ratio of fat to carbohydrate in the
diet. Further studies are needed to determine whether diet
affects adropin expression in primates or adropin expression
correlates with macronutrient preferences. The latter finding
would not be without precedent. For example, fibroblast
growth factor-21 (FGF21) regulates consumption of protein
and sugars (65, 66), whereas melanocortin-4 receptor (MC4R)
signaling in the central nervous system regulates fat and
sucrose preferences (67).
In summary, these results strongly indicate that low adropin
expression is associated with metabolic dysregulation in a non-
human primate model of sugar (fructose) diet-induced meta-
bolic syndrome. A strength of the study is that the data were
derived from experiments conducted in nonhuman primates,
suggesting a higher probability of clinical relevance (30–
32).The diurnal profile of ENHO transcript indicates that peak
adropin expression and signaling are temporally linked to food
intake and occurwhen feeding behavior ismaximal in primates.
Peaks in ENHO expression coincide with those of genes linked
to signaling from cell-surface G-protein–coupled receptors
and receptor tyrosine kinases. If gene expression data are indic-
ative of protein levels, then the peak hepatic ENHO expression
appears to coincide with enhanced responsiveness of the liver
to neural and hormonal signals ofmetabolic status. Low plasma
adropin concentrations are predictive of a pre-diabetic pheno-
type at an earlier age in rhesus macaques and may also be
related to increased body adiposity. These results provide a
strong rationale for further studies investigating relationships
between rhythms in adropin signaling and metabolic homeo-
stasis, particularly the metabolic effects of adropin administra-
tion/replacement in nonhuman primate models.
Experimental procedures
In silico analysis in a nonhuman primate diurnal
transcriptome atlas
Animal studies used to generate the atlas (GSE98965) were
reported elsewhere by the laboratories responsible for conduct-
ing the experiments (34). Briefly, animals were acclimated to
housing in semi-natural conditions under 12-h light/12-h dark
cycles for 1month; meals (fruits and primatemeal pellets) were
provided at ZT3 and ZT9. The dataset contains 29,202 genes
from 108 tissues of P. anubis collected at 12 time points over
24 h (ZT00, ZT02, ZT04, ZT06, ZT08, ZT10, ZT12, ZT14,
ZT16, ZT18, ZT20, andZT22, ZT0 start of the light cycle and
ZT12 start of the dark cycle).
Processed RPKMvalues were downloaded from theNational
Institutes of Health GEO website (GEO accession number
GSE98965), decompressed, and analyzed in R and Bioconduc-
tor. Gene symbols were updated by querying the BioMart
“panubis_gene_ensembl” dataset and matching Ensembl IDs
using the R “biomaRt” package (68).
ENHO expression exhibits a dynamic profile in baboon tis-
sues. To explore whether the profile is unique or shared by a
cluster of genes regulated by the common regulatory pathway,
we screened for genes exhibiting similar profiles during the
light and dark periods. The dataset was consolidated by remov-
ing genes with zero counts at all time points. A Pearson corre-
lation coefficient matrix was calculated between all gene pair-
ings. Correlation coefficients were then extracted between the
expression profile of all genes and ENHO. This matrix was
ranked by correlation coefficient from the highest (
1, ENHO:
ENHO) to lowest (0.9471788, ENHO:ABCB7). An example
correlationmatrix is shown in Table S1. GSEAwas then used to
identify globally enriched or depleted gene sets/pathways in the
Molecular Signatures Database (MSigDB Version 5.2, http://
software.broadinstitute.org/gsea/msigdb/index.jsp)5 (69) in
genes showing high- or low-correlation coefficients.We usedR
values as selection criteria (R0.7 or0.7 for liver and0.9
or0.9 for the unbiased screen of all genes in all tissues). To
perform the GSEA, we examined specific gene sets/pathways,
enrichment, or depletion among the ENHO-coexpressed genes
using the fgsea package (http://bioconductor.org/packages/
release/bioc/html/fgsea.html)5 in R (69, 70, 76). Enriched or
depleted genes within significant gene sets/pathways were
extracted using the “fgsea” function provided in the package.
For comparing the pattern of correlations between ENHO
expression and gene clusters between tissues, we computed
Pearson correlation coefficients between ENHO and all other
genes in the dataset based on expression levels across the dif-
ferent time points, producing a column vector for each tissue.
We then computed the distance between each pair of the tis-
sues by obtaining a sample-wise correlation matrix using the
column vectors obtained above. Finally, the correlation matrix
was subjected to unsupervised hierarchical clustering to iden-
tify clusters of tissues with similar ENHO regulatory pathways
(i.e. time-dependent expression of ENHO-coregulated genes).
ENHO promoter features were analyzed using Integrative
GenomeBrowser (Version 2.4). Various tracks, including “CpG
islands,” “SiPhy” score using 10-mer (sequence conservation
score, higher scores indicate stronger conservation) (71), and
“phastCons” (conservation score based on phylogenetic hidden
Markov model) (72), were used to analyze CpG density and
sequence conservation of the ENHO promoter region across 46
vertebrate species. ENCODE datasets (https://www.encode
project.org)5 (36) revealed DNA methylation and histone
methylation status at the ENHO promoter region in HepG2
cells.
5 Please note that the JBC is not responsible for the long-term archiving and
maintenance of this site or any other third party hosted site.
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Rhesusmacaquemodel of diet-induced obesity, insulin resis-
tance, and dyslipidemia
Plasma adropin concentrations were measured in samples
from a previously published group of rhesus macaques (31, 35,
39). In brief, 59 adult male rhesus macaques maintained by the
CaliforniaNational Primate ResearchCenter (CNPRC,Univer-
sity of California, Davis) were provided ad libitum access to a
high-protein diet (LabDiet 5047: 30.4% kcal/protein, 13.2%
kcal/fat, and 56.4% kcal/carbohydrates) and water. Dietary car-
bohydrates are primarily starch; fats are primarily linoleic acid
and monounsaturated and saturated fatty acids. After collec-
tion of baseline biometric and plasma samples, animals were
provided 500ml/day of a flavored 15% fructose solution provid-
ing 75 g or 300 kcal/day. Fasting plasma samples and body
weightmeasurements were collected after 1 and 3months. The
research protocols were approved both by the Institutional
Animal Care and Use Committees of the University of Califor-
nia, Davis, and conducted in accordance with the Department
of Agriculture Animal Welfare Act and National Institutes of
Health Guidelines for the Care and Use of Animals.
Blood chemistries
Plasma insulin, leptin, and adiponectin concentrations were
measured by RIA (EMDMillipore, Billerica,MA). Plasma adro-
pin concentrations were measured by ELISA (Peninsula Labo-
ratories, San Carlos, CA). Plasma glucose concentrations were
measured with a YSI Glucose Analyzer (YSI Life Sciences).
Plasma total cholesterol, HDL cholesterol (HDL-C), direct LDL
cholesterol (LDL-C), TG, ApoA1, ApoB, ApoC3, and ApoE
concentrations were determined by using a Polychem Chemis-
try Analyzer (PolyMedCo). VLDL-C was calculated by sub-
tracting HDL-C and LDL-C from total cholesterol.
Measurement of lipoprotein particle size
Particle concentrations of VLDL, IDL, LDL, and HDL sub-
fractions were analyzed in specific particle-size intervals using
ion mobility (IM), which uniquely allows for direct particle
quantification as a function of particle diameter (73), following
a procedure to remove other plasma proteins (74). The IM
instrument utilizes an electrospray to create an aerosol of par-
ticles, which then pass through a differential mobility analyzer
coupled to a particle counter.
Particle concentrations (nmol/liter) were determined for
subfractions defined by the following size intervals (nm):VLDL:
large (42.40–54.70),medium (33.50–42.39), and small (29.60–
33.49); IDL: large (25.00–29.59) and small (23.33–24.99); LDL:
large (22.0–23.32), medium (21.41–21.99), small (20.82–
21.40), and very small (18.0–20.81); and HDL: large (10.50–
14.50) and small (7.65–10.49). Peak LDL diameter (nm) was
determined as described previously (73).
Adropin transgenicmice
Adropin transgenic mice expressing a synthetic gene driven
by the human-actin promoter have been described previously
(1, 8, 10). Fat mass, fat-free mass, and free H2O measured by
NMR (Bruker Minispec; Bruker, Billerica, MA) and analyzed
using regression was described previously (75). Studies using
adropin transgenic mice were reviewed and approved by the
Saint Louis University Institutional Animal Care and Use
Committee.
Statistical analysis
Statistical analysis used IBM SPSS Statistics (Version 24).
Relationships between adropin and indices of body weight and
metabolic homeostasis were assessed using log-transformed
data in simple modeling andmultiple regression. Animals were
also separated into groups ranked by baseline plasma adropin
concentration (low, n 20; medium, n 19; or high, n 20).
Group differences were initially assessed for significance using
parametric or, if required, nonparametric tests (Kruskal-Wallis
test). Interactions between diet and adropin groups were
ranked by baseline or 	s using repeated measures ANOVA.
Variables exhibiting significant differences between adropin
groups were further explored using univariate analysis (inde-
pendent variable: adropin group) with post-hoc comparisons.
Potentially confounding variables (age, body weight) were con-
trolled for as required by inclusion as covariates in the analysis.
Determinants of plasma adropin concentrations were calcu-
lated using linear regression with log-transformed data.
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